AVITA MedicalASX:AVH -2.25%57 Days Payable is 216.00 as of Mar. 2026, which is 19% below its 10-year median of 266.24. GuruFocus rates ASX:AVH with a GF Score™ of 57/100 and a GF Value™ of A$2.92 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 795 Medical Devices & Instruments companies, AVITA Medical ranks better than 86.16% on this metric.
The historical rank and industry rank for AVITA Medical's Days Payable or its related term are showing as below:
ASX:AVH'
s Days Payable Range Over the Past 10 Years
Min: 159.39 Med: 266.24 Max: 1189.29
Current: 217.81
During the past 13 years, AVITA Medical's highest Days Payable was 1189.29. The lowest was 159.39. And the median was 266.24.
ASX:AVH's Days Payable is ranked better than 86.16% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 67.87
vs ASX:AVH: 217.81
AVITA Medical's Days Payable
declined
from Mar. 2025 (240.59) to Mar. 2026 (216.00).
It may suggest that AVITA Medicalaccelerated paying its suppliers.
AVITA Medical Days Payable Related Terms
AVITA Medical Days Payable Historical Data
* Premium members only.
The historical data trend for AVITA Medical's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:AVH vs NNOX, MXCT, SNWV: Days Payable Comparison
For the Medical Devices subindustry, AVITA Medical's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AVITA Medical Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, AVITA Medical's Days Payable distribution charts can be found below:
* The bar in red indicates where AVITA Medical's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
AVITA Medical's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AVITA Medical (ASX:AVH) has a Days Payable of 216.00 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on AVITA Medical and its competitors. This is 19% below median its historical median of 266.24. Over the past decade, AVITA Medical's Days Payable has ranged from 159.39 to 1,189.29. According to the industry distribution chart, AVITA Medical ranks #110 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 13.8%.
Is AVITA Medical's Days Payable too high?
AVITA Medical's current Days Payable of 216.00 is 19% below median its 10-year median of 266.24. Over the past 10 years, this metric has ranged from a low of 159.39 to a high of 1,189.29. The Medical Devices & Instruments industry median Days Payable is 67.87. AVITA Medical's value of 216.00 is 218.3% above this industry median. Based on the distribution chart, AVITA Medical ranks #110 out of 795 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, AVITA Medical has a GF Score™ of 57/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does AVITA Medical's Days Payable compare to NNOX and MXCT?
According to the Medical Devices & Instruments industry distribution chart, AVITA Medical ranks #110 out of 795 companies for Days Payable. This places AVITA Medical in the top 14% of its industry — outperforming the majority of peers. The industry median Days Payable is 67.87. AVITA Medical's value of 216.00 is 218.3% above this benchmark. Historically, AVITA Medical's own Days Payable has ranged from 159.39 to 1,189.29 over the past decade. While the company's 10-year median is 266.24 vs. the industry median of 67.87, AVITA Medical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 67.87, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AVITA Medical's current Days Payable of 216.00 is 218.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on AVITA Medical and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 67.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AVITA Medical's current Days Payable is 216.00, which is 19% below median its own 10-year median of 266.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AVITA Medical stock overvalued right now?
Based on GuruFocus' analysis, AVITA Medical (ASX:AVH) is currently considered Possible Value Trap. The stock's GF Value™ is A$2.92, compared to a current price of A$1.09 — trading 62.8% below its estimated fair value. The current Days Payable is 216.00, which is 19% below median its 10-year median of 266.24 and 218.3% above the Medical Devices & Instruments industry median of 67.87. AVITA Medical's overall GF Score™ is 57/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For AVITA Medical (ASX:AVH), the current Days Payable is 216.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AVITA Medical (ASX:AVH) Overvalued in 2026?
Based on GuruFocus' analysis, AVITA Medical stock appears to be undervalued.
The current stock price of A$1.09 is trading 62.8% below its estimated GF Value™ of A$2.92.
GuruFocus considers AVITA Medical to be Possible Value Trap.
Key valuation signals for ASX:AVH:
Days Payable: 216.00 (19% below median its 10-year median of 266.24)
GF Value™: A$2.92 vs. price of A$1.09 (62.8% below fair value)
Industry Position: 218.3% above the Medical Devices & Instruments median (#110 of 795)
No single metric tells the full story. See the ASX:AVH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.
57GF Score
Get the complete analysis for ASX:AVH
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:AVH has been successfully added to your 
